Cancers 2010, 2(2), 955-969; doi:10.3390/cancers2020955
Systemic Therapy of Non-Resectable Metastatic Melanoma
Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany
*
Author to whom correspondence should be addressed.
Received: 8 March 2010 / Revised: 11 May 2010 / Accepted: 12 May 2010 / Published: 26 May 2010
(This article belongs to the Special Issue Current Concepts in the Diagnosis and Treatment of Cutaneous Melanoma)
View Full-Text
|
Download PDF [123 KB, uploaded 26 May 2010]
Abstract
In advanced metastatic melanoma (non-resectable stage III/IV), the prognosis still remains poor, with median survival times between six and twelve months. Systemic therapeutic approaches for metastatic melanoma include chemotherapy, immunotherapy, immunochemotherapy, small molecules and targeted therapy. In this review, we will focus on the various treatment modalities as well as new agents used for targeted therapy. View Full-TextKeywords:
melanoma; metastatic; chemotherapy; targeted therapy; small molecules
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).
Share & Cite This Article
MDPI and ACS Style
Orouji, A.; Goerdt, S.; Utikal, J. Systemic Therapy of Non-Resectable Metastatic Melanoma. Cancers 2010, 2, 955-969.